

Paulo Bettencourt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7965347/publications.pdf>

Version: 2024-02-01

176
papers

7,367
citations

125106

35
h-index

66518

82
g-index

180
all docs

180
docs citations

180
times ranked

9887
citing authors

#	ARTICLE	IF	CITATIONS
1	CA ² variation in acute heart failure: a single-centre analysis. <i>ESC Heart Failure</i> , 2022, 9, 1018-1026.	1.4	7
2	The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study. <i>Arthritis Research and Therapy</i> , 2022, 24, 9.	1.6	4
3	NT-proBNP for heart failure diagnosis in Primary Care: Costs or savings? A budget impact study. <i>Revista Portuguesa De Cardiologia</i> , 2022, 41, 183-193.	0.2	7
4	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 755-759.	2.5	31
5	Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110938.	2.5	15
6	Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021, 60, e181-e183.	0.9	1
7	Glucose variability predicts 6-month mortality in patients hospitalized with acute heart failure. <i>Internal and Emergency Medicine</i> , 2021, 16, 2121-2128.	1.0	6
8	Dynamics of growth differentiation factor 15 in acute heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2527-2534.	1.4	10
9	Acute on chronic heart failure—Which variations on B-type natriuretic peptide levels?. <i>Journal of the American College of Emergency Physicians Open</i> , 2021, 2, e12448.	0.4	3
10	The prognostic impact of uric acid in acute heart failure according to coexistence of diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3377-3383.	1.1	3
11	Checklist para A Prática-Alta de Internamento por Insuficiência Cardíaca. <i>Revista De Medicina Interna, Neurologia, Psiquiatria, Neurocirurgia, Dermato-venereologia Medicina Interna</i> , 2021, 28, 76-81.	0.0	0
12	From left ventricular ejection fraction to cardiac hemodynamics: role of echocardiography in evaluating patients with heart failure. <i>Heart Failure Reviews</i> , 2020, 25, 217-230.	1.7	27
13	Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 21-26.	0.6	10
14	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 517-541.	0.2	8
15	Non-criteria antiphospholipid syndrome: A nomenclature proposal. <i>Autoimmunity Reviews</i> , 2020, 19, 102689.	2.5	37
16	Qualitative serology in patients recovered from SARS CoV 2 infection. <i>Journal of Infection</i> , 2020, 81, e120-e121.	1.7	9
17	Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 419-436.	1.3	16
18	The cholesterol paradox may be attenuated in heart failure patients with diabetes. <i>Minerva Medica</i> , 2020, 110, 507-514.	0.3	3

#	ARTICLE	IF	CITATIONS
19	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020, 39, 517-541.	0.2	0
20	C-reactive protein decrease associates with mortality reduction only in heart failure with preserved ejection fraction. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 23-29.	0.6	10
21	Diastolic Function Is Impaired in Patients With Prehypertension: Data From the EPIPorto Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 926-934.	0.4	3
22	Age affects the prognostic impact of diabetes in chronic heart failure. <i>Acta Diabetologica</i> , 2018, 55, 271-278.	1.2	9
23	Impact of the 2016 ASE/EACVI recommendations on the prevalence of diastolic dysfunction in the general population. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 380-386.	0.5	125
24	Is there a C-reactive protein value beyond which one should consider infection as the cause of acute heart failure?. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 40.	0.7	7
25	La función diastólica se altera en pacientes con prehipertensión: datos del estudio EPIPorto. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 926-934.	0.6	6
26	Atrial fibrillation, a difficulty in the heart failure screening with natriuretic peptides. <i>Heart</i> , 2018, 104, 1236.2-1237.	1.2	0
27	Left atrial volume index is critical for the diagnosis of heart failure with preserved ejection fraction. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 304-309.	0.6	16
28	A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure. <i>International Journal of Cardiology</i> , 2018, 250, 215-222.	0.8	3
29	Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15. <i>ESC Heart Failure</i> , 2018, 5, 1017-1022.	1.4	29
30	Prognostic Effect of Renal Function in Ambulatory Patients With Heart Failure and Reduced Ejection Fraction: The Kidney Is a Marker of Cardiac Function. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1325-1332.	0.8	10
31	Quality of Life Predicts Survival and Hospitalisation in a Heart Failure Portuguese Population. <i>Applied Research in Quality of Life</i> , 2017, 12, 35-48.	1.4	7
32	Prognostic prediction in acute heart failure patients with extreme BNP values. <i>Biomarkers</i> , 2017, 22, 715-722.	0.9	3
33	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	1.2	244
34	Meta-Analysis of Soluble Suppression of Tumorogenicity-2 and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	1.9	104
35	Reply. <i>European Journal of Heart Failure</i> , 2017, 19, 961-961.	2.9	1
36	Long-term prognosis after acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 845-850.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Prognostic Effect of the Dose of Loop Diuretic Over 5 Years in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 589-593.	0.7	8
38	Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2017, 241, 249-254.	0.8	6
39	Interpretação dos peptídeos natriuréticos tipo B na era dos antagonistas da neprilina/receptores da angiotensina (ARNIs). <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 881-884.	0.2	3
40	Relaxin serum levels in acute heart failure are associated with pulmonary hypertension and right heart overload. <i>European Journal of Heart Failure</i> , 2017, 19, 218-225.	2.9	20
41	Interpretation of B-type natriuretic peptides in the era of angiotensin receptor-neprilysin inhibitors. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 881-884.	0.2	2
42	Natriuretic Peptide System Activation in Acute Heart Failure Patients with Diabetes. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-5.	1.0	2
43	Acute heart failure and rhabdomyolysis: a clue for the diagnosis of polymyositis with cardiac involvement. <i>Reumatismo</i> , 2017, 69, 78.	0.4	4
44	Insulin treatment may not be associated with worse prognosis in acute heart failure diabetic patients. <i>Minerva Endocrinology</i> , 2017, 42, 318-324.	0.6	3
45	IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort. <i>PLoS ONE</i> , 2016, 11, e0163474.	1.1	5
46	Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients. <i>JACC: Heart Failure</i> , 2016, 4, 736-745.	1.9	11
47	Validity of the Seattle Heart Failure Model for prognosis in a population at low coronary heart disease risk. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 653-658.	0.6	4
48	A closer look at acute heart failure: Putting Portuguese and European data into perspective. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 291-304.	0.2	13
49	Impact of Chronic Nitrate Therapy in Patients With Ischemic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 466-470.	1.0	2
50	A closer look at acute heart failure: Putting Portuguese and European data into perspective. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 291-304.	0.2	10
51	Evaluation of Innate Immunity Biomarkers on Admission and at Discharge From an Acute Heart Failure Episode. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 1183-1190.	0.9	1
52	Liver cytolysis in acute heart failure: What does it mean? Clinical profile and outcomes of a prospective hospital cohort. <i>International Journal of Cardiology</i> , 2016, 221, 422-427.	0.8	2
53	Usefulness of the Hepatocyte Growth Factor as a Predictor of Mortality in Patients Hospitalized With Acute Heart Failure Regardless of Ejection Fraction. <i>American Journal of Cardiology</i> , 2016, 118, 543-549.	0.7	6
54	Depression predicts mortality and hospitalization in heart failure: A six-years follow-up study. <i>Journal of Affective Disorders</i> , 2016, 201, 162-170.	2.0	26

#	ARTICLE	IF	CITATIONS
55	Is there a heart rate paradox in acute heart failure?. International Journal of Cardiology, 2016, 203, 409-414.	0.8	11
56	Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clinical Research in Cardiology, 2016, 105, 489-507.	1.5	35
57	A new tool to measure hydration status in acute heart failure – Is bioelectrical impedance vector analysis (BIVA) making its way to the wards?. Revista Clinica Espanola, 2016, 216, 126-127.	0.2	4
58	Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators. Current Drug Targets, 2016, 17, 1206-1223.	1.0	13
59	<scp>ExtraHF</scp> survey: the first European survey on implementation of exercise training in heart failure patients. European Journal of Heart Failure, 2015, 17, 631-638.	2.9	69
60	Infective Endocarditis Presenting as Acute Renal Failure and Unusual Complications. Internal Medicine, 2015, 54, 1259-1263.	0.3	2
61	Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 61.	1.6	29
62	Higher BMI in heart failure patients is associated with longer survival only in the absence of diabetes. Journal of Cardiovascular Medicine, 2015, 16, 576-582.	0.6	17
63	Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?. European Journal of Heart Failure, 2015, 17, 936-944.	2.9	30
64	The lymphocyte-to-monocyte ratio: An added value for death prediction in heart failure. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 1033-1040.	1.1	40
65	Measuring renal function in acute heart failure: A place for old and new equations. International Journal of Cardiology, 2015, 196, 70-72.	0.8	1
66	Utility of the SENIORS elderly heart failure risk model applied to the RICA registry of acute heart failure. International Journal of Cardiology, 2015, 182, 449-453.	0.8	23
67	Predictors of Six-Month Mortality in BNP-Matched Acute Heart Failure Patients. American Journal of Cardiology, 2015, 116, 744-748.	0.7	20
68	Direct, inflammation-mediated and blood-pressure-mediated effects of total and abdominal adiposity on diastolic function: EPIPorto study. International Journal of Cardiology, 2015, 191, 64-70.	0.8	8
69	Heart failure with reduced ejection fraction: Should we submit patients without angina to coronary angiography?. International Journal of Cardiology, 2015, 190, 131-132.	0.8	10
70	Association between plasma leptin and adiponectin levels and diastolic function in the general population. Expert Opinion on Therapeutic Targets, 2015, 19, 1283-1291.	1.5	27
71	Assessment of cardiovascular physiology using magnetic resonance myocardial stress testing reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, Q67.	1.6	0
72	Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 4.	2.7	113

#	ARTICLE	IF	CITATIONS
73	Complement C3c and C4c as predictors of death in heart failure. <i>IJC Metabolic & Endocrine</i> , 2015, 7, 31-35.	0.5	3
74	Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2015, 104, 491-499.	1.5	54
75	Prognostic Value of Osteoprotegerin in Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1266-1271.	0.8	7
76	Competing Risk of Cardiac Status and Renal Function During Hospitalization for Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 751-761.	1.9	43
77	Predictors of Natriuretic Peptide Non-Response in Patients Hospitalized With Acute Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 69-74.	0.7	11
78	Medication Adherence to Specific Drug Classes in Chronic Heart Failure. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 1018-1026.	2.2	33
79	Toxic Dilated Cardiomyopathy: Recognizing a Potentially Reversible Disease. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 102, e37.	0.3	2
80	Assessment of cardiovascular disease risk using immunosensors for determination of C-reactive protein levels in serum and saliva: a pilot study. <i>Bioanalysis</i> , 2014, 6, 1459-1470.	0.6	14
81	High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients. <i>Cardiology Research and Practice</i> , 2014, 2014, 1-9.	0.5	11
82	A Challenging Case of an Ectopic Cushing Syndrome. <i>Case Reports in Medicine</i> , 2014, 2014, 1-8.	0.3	5
83	The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial. <i>Nephrology</i> , 2014, 19, 149-156.	0.7	2
84	Impaired resolution of inflammation in human chronic heart failure. <i>European Journal of Clinical Investigation</i> , 2014, 44, 527-538.	1.7	43
85	Systolic dysfunction and diastolic dysfunction do not influence medium-term prognosis in patients with cirrhosis. <i>European Journal of Internal Medicine</i> , 2014, 25, 241-246.	1.0	35
86	Left atrial function is impaired in cirrhosis: a speckle tracking echocardiographic study. <i>Hepatology International</i> , 2014, 8, 146-153.	1.9	13
87	High-dose spironolactone changes renin and aldosterone levels in acutely decompensated heart failure. <i>Cor Et Vasa</i> , 2014, 56, e463-e470.	0.1	9
88	Prognostic value of worsening renal function in outpatients with chronic heart failure. <i>European Journal of Internal Medicine</i> , 2014, 25, 662-668.	1.0	10
89	Low prealbumin is strongly associated with adverse outcome in heart failure. <i>Heart</i> , 2014, 100, 1780-1785.	1.2	50
90	A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European collaboration on Acute decompensated Heart Failure: The LAN-HF Score. <i>Heart</i> , 2014, 100, 115-125.	1.2	106

#	ARTICLE	IF	CITATIONS
91	Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: Findings from the RICA registry. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 410-419.	1.1	53
92	Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. <i>European Journal of Internal Medicine</i> , 2014, 25, 67-72.	1.0	71
93	Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute Decompensated Heart Failure. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 104, 308-14.	0.3	8
94	Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. <i>Clinical Research in Cardiology</i> , 2013, 102, 745-753.	1.5	26
95	Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. <i>International Journal of Cardiology</i> , 2013, 165, 51-55.	0.8	74
96	Left-sided infective endocarditis: Analysis of in-hospital and medium-term outcome and predictors of mortality. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 777-784.	0.2	21
97	Influence of socioeconomic status on therapy and prognosis after an acute heart failure episode. <i>International Journal of Cardiology</i> , 2013, 168, 4985-4987.	0.8	4
98	Does pre-albumin predict in-hospital mortality in heart failure?. <i>International Journal of Cardiology</i> , 2013, 166, 758-760.	0.8	11
99	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2013, 368, 513-523.	13.9	524
100	Systolic and diastolic dysfunction in cirrhosis: a tissueâ€Doppler and speckle tracking echocardiography study. <i>Liver International</i> , 2013, 33, 1158-1165.	1.9	86
101	Is the Blood Pressure Paradox Observed in All Heart Failure Patients?. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	7
102	Dipeptidyl peptidase IV and Mortality After an Acute Heart Failure Episode. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 138-142.	0.8	14
103	Atrial Septal Defect in a Very Old Woman. <i>Cardiology Research</i> , 2013, 4, 41-44.	0.5	0
104	Statin-Induced Low Cholesterol is Not Associated With Poor Outcome in Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 284-290.	1.0	10
105	Diagnostic value of patterns of symptoms and signs of heart failure: application of latent class analysis with concomitant variables in a cross-sectional study. <i>BMJ Open</i> , 2012, 2, e001510.	0.8	12
106	939 AUTOIMMUNE HEPATITIS IN HOSPITALIZED PATIENTS: CASE SERIES REPORT OF PATIENTS ADMITTED TO AN INTERNAL MEDICINE DEPARTMENT. <i>Journal of Hepatology</i> , 2012, 56, S366-S367.	1.8	0
107	Valvular lesions in patients with systemic lupus erythematosus and antiphospholipid syndrome: An old disease but a persistent challenge. <i>Revista Portuguesa De Cardiologia</i> , 2012, 31, 295-299.	0.2	15
108	Prognostic Significance of Applying the European Society of Cardiology Consensus Algorithm for Heart Failure With Preserved Systolic Function Diagnosis. <i>Clinical Cardiology</i> , 2012, 35, 770-778.	0.7	11

#	ARTICLE	IF	CITATIONS
109	Natriuretic peptides in aortic stenosis. <i>Revista Portuguesa De Cardiologia</i> , 2012, 31, 655-660.	0.2	3
110	Nutritional markers and prognosis in cardiac cachexia. <i>International Journal of Cardiology</i> , 2011, 146, 359-363.	0.8	56
111	O1-4.5 Prognostic value of a novel classification scheme of clinical symptoms and signs of heart failure adjusted for major confounders. <i>Journal of Epidemiology and Community Health</i> , 2011, 65, A15-A15.	2.0	0
112	Third year medical students perceptions towards learning communication skills: Implications for medical education. <i>Patient Education and Counseling</i> , 2011, 85, e265-e271.	1.0	16
113	Attitudes and anxiety levels of medical students towards the acquisition of competencies in communication skills. <i>Patient Education and Counseling</i> , 2011, 85, e272-e277.	1.0	19
114	Indirect calibration between clinical observers - application to the New York Heart Association functional classification system. <i>BMC Research Notes</i> , 2011, 4, 276.	0.6	14
115	Neutrophil Gelatinase-Associated Lipocalin in the Diagnosis of Type 1 Cardio-Renal Syndrome in the General Ward. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 476-481.	2.2	84
116	Prognostic Implications of Diuretic Dose in Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011, 16, 185-191.	1.0	13
117	Population-Based Study on the Prevalence of Spirometric Obstructive Pattern in Porto, Portugal. <i>Respiratory Care</i> , 2011, 56, 619-625.	0.8	4
118	B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. <i>Liver International</i> , 2010, 30, 1059-1066.	1.9	46
119	Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 106-111.	1.2	40
120	Higher C-reactive Protein Predicts Worse Prognosis in Acute Heart Failure Only in Noninfected Patients. <i>Clinical Cardiology</i> , 2010, 33, 708-714.	0.7	26
121	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , 2010, 376, 875-885.	6.3	2,119
122	Prevalence and characteristics of sleep apnoea in patients with stable heart failure: Results from a heart failure clinic. <i>BMC Pulmonary Medicine</i> , 2010, 10, 9.	0.8	21
123	BNP at discharge in acute heart failure patients: Is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. <i>International Journal of Cardiology</i> , 2010, 145, 209-214.	0.8	39
124	Wet BNP, fluid and hemodynamic status at discharge in acute heart failure – Reply. <i>International Journal of Cardiology</i> , 2010, 145, 336-337.	0.8	1
125	Prognostic Value of Discharge Levels of N-Terminal Pro-Brain Natriuretic Peptide in 1301 Patients: A European Collaborative Study. <i>Journal of Cardiac Failure</i> , 2010, 16, S66.	0.7	0
126	Aminoterminal B-Type Natriuretic Peptide (NT-proBNP) in End-Stage Renal Failure Patients on Regular Hemodialysis: Does It Have Diagnostic and Prognostic Implications?. <i>Nephron Clinical Practice</i> , 2009, 111, c182-c188.	2.3	6

#	ARTICLE	IF	CITATIONS
127	Variability of High-Sensitivity C-Reactive Protein in Chronic Heart Failure. <i>Cardiology</i> , 2009, 113, 180-183.	0.6	1
128	Adiponectin is increased in cardiac cachexia irrespective of body mass index. <i>European Journal of Heart Failure</i> , 2009, 11, 567-572.	2.9	44
129	The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure. <i>European Journal of Heart Failure</i> , 2009, 11, 185-190.	2.9	11
130	Spironolactone Therapy in Heart Failure Patients with Chronic Kidney Disease. <i>Clinical Cardiology</i> , 2009, 32, 597-597.	0.7	2
131	Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review. <i>Journal of Cardiac Failure</i> , 2009, 15, 256-266.	0.7	120
132	Natriuretic peptide system is not exhausted in severe heart failure. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 39-43.	0.6	5
133	Safety of Spironolactone Use in Ambulatory Heart Failure Patients. <i>Clinical Cardiology</i> , 2008, 31, 509-513.	0.7	31
134	Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for Inpatient Monitoring and Treatment Guidance of Acute Destabilized Heart Failure. <i>American Journal of Cardiology</i> , 2008, 101, S67-S71.	0.7	17
135	Cholesterol – A marker of nutritional status in mild to moderate heart failure. <i>International Journal of Cardiology</i> , 2008, 129, 65-68.	0.8	26
136	Health-related quality of life and stages of heart failure. <i>International Journal of Cardiology</i> , 2008, 129, 238-244.	0.8	29
137	Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. <i>American Heart Journal</i> , 2008, 155, 521-525.	1.2	96
138	Depressive Symptoms and Heart Failure Stages. <i>Psychosomatics</i> , 2008, 49, 42-48.	2.5	17
139	New cardiovascular biomarkers: clinical implications in patients with valvular heart disease. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 945-954.	0.6	11
140	Validation of a risk score to estimate cardiac risk in subjects from the general population on cardioactive treatment. <i>European Journal of Heart Failure</i> , 2008, 10, 621-622.	2.9	0
141	Clinical syndrome suggestive of heart failure is frequently attributable to non-cardiac disorders - population-based study. <i>European Journal of Heart Failure</i> , 2007, 9, 391-396.	2.9	28
142	Obstructive sleep apnoea and adipocyte death: Authors reply. <i>European Journal of Heart Failure</i> , 2007, 9, 104-105.	2.9	1
143	Amino Terminal B-Type Natriuretic Peptide, Renal Function, and Prognosis in Acute Heart Failure: A Hospital Cohort Study. <i>Journal of Cardiac Failure</i> , 2007, 13, 275-280.	0.7	19
144	Prognosis of decompensated heart failure patients with preserved systolic function is predicted by NT-proBNP variations during hospitalization. <i>International Journal of Cardiology</i> , 2007, 117, 75-79.	0.8	25

#	ARTICLE	IF	CITATIONS
145	Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities – cross-sectional study of the general population. BMC Cardiovascular Disorders, 2007, 7, 17.	0.7	52
146	526 Use of beta blockers in HF patients with chronic obstructive pulmonary disease. European Journal of Heart Failure, Supplement, 2007, 6, 119-119.	0.2	0
147	453 Safety of spironolactone use in ambulatory HF patients. European Journal of Heart Failure, Supplement, 2007, 6, 96-97.	0.2	0
148	Prognosis of decompensated heart failure: role of NT-proBNP. Revista Portuguesa De Cardiologia, 2007, 26, 535-45.	0.2	9
149	Intraindividual Variation of Amino-Terminal Pro-B-Type Natriuretic Peptide Levels in Patients With Stable Heart Failure. American Journal of Cardiology, 2006, 98, 1248-1250.	0.7	58
150	Heart failure and sleep apnoea: To sleep perchance to dream. European Journal of Heart Failure, 2006, 8, 227-236.	2.9	12
151	Population based study on the prevalence of the stages of heart failure. Heart, 2006, 92, 1161-1163.	1.2	16
152	Effect of Saline Load and Metoclopramide on the Renal Dopaminergic System in Patients with Heart Failure and Healthy Controls. Journal of Cardiovascular Pharmacology, 2005, 45, 197-203.	0.8	14
153	Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives. Heart, 2005, 91, 1489-1494.	1.2	37
154	Heart failure and health related quality of life. Clinical Practice and Epidemiology in Mental Health, 2005, 1, 19.	0.6	62
155	N-Terminal – Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients. Circulation, 2004, 110, 2168-2174.	1.6	644
156	The effect of dietary sodium restriction on neurohumoral activity and renal dopaminergic response in patients with heart failure. European Journal of Heart Failure, 2004, 6, 593-599.	2.9	65
157	NT-proBNP and BNP: biomarkers for heart failure management. European Journal of Heart Failure, 2004, 6, 359-363.	2.9	70
158	Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. International Journal of Cardiology, 2004, 93, 45-48.	0.8	80
159	P3386 Role of brain natriuretic peptide in identifying the origin of pulmonary edema in critical patients. European Heart Journal, 2003, 24, 651.	1.0	0
160	P2327 Health-related quality of life and heart failure. European Heart Journal, 2003, 24, 450.	1.0	0
161	Impact of cardiovascular risk factors in an urban sample of Portuguese adults according to the Framingham risk prediction models. Revista Portuguesa De Cardiologia, 2003, 22, 511-20.	0.2	1
162	B-Type Natriuretic Peptide Is Related to Left Ventricular Mass in Hypertensive Patients but Not in Athletes. Cardiology, 2002, 98, 113-115.	0.6	31

#	ARTICLE	IF	CITATIONS
163	Effect of a heart failure clinic on survival and hospital readmission in patients discharged from acute hospital care. <i>European Journal of Heart Failure</i> , 2002, 4, 353-359.	2.9	45
164	Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. <i>American Journal of Medicine</i> , 2002, 113, 215-219.	0.6	91
165	The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure. <i>American Heart Journal</i> , 2002, 143, 391-397.	1.2	14
166	Brain Natriuretic Peptide (Nesiritide) in the Treatment of Heart Failure. <i>Cardiovascular Drug Reviews</i> , 2002, 20, 27-36.	4.4	16
167	Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. <i>Clinical Science</i> , 2001, 100, 557-566.	1.8	22
168	Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. <i>Clinical Science</i> , 2001, 100, 557.	1.8	12
169	Heart failure, aging, and renal synthesis of dopamine. <i>American Journal of Kidney Diseases</i> , 2001, 38, 502-509.	2.1	11
170	Evaluation of Brain Natriuretic Peptide in the Diagnosis of Heart Failure. <i>Cardiology</i> , 2000, 93, 19-25.	0.6	62
171	Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. <i>Clinical Science</i> , 2000, 99, 195-200.	1.8	7
172	Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. <i>Clinical Science</i> , 2000, 99, 195.	1.8	4
173	Clinical Significance of Brain Natriuretic Peptide in Patients with Postmyocardial Infarction. <i>Clinical Cardiology</i> , 2000, 23, 921-927.	0.7	33
174	Predictors of prognosis in patients with stable mild to moderate heart failure. <i>Journal of Cardiac Failure</i> , 2000, 6, 306-313.	0.7	107
175	Brain natriuretic peptide as a marker of cardiac involvement in hypertension. <i>International Journal of Cardiology</i> , 1999, 69, 169-177.	0.8	30
176	Angiotensin-converting enzyme inhibitors in heart failure: Physicians' prescribing behavior. <i>Journal of Cardiac Failure</i> , 1997, 3, 295-302.	0.7	14